Long noncoding RNA ATB promotes the epithelial−mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer

Li, Ronghui; Chen, Min; Liu, Jing; Shao, Changchun; Guo, Chunbao; Wei, Xiaolong; Li, Yaochen; Huang, Wen‐He; Zhang, Guo‐Jun

doi:10.1038/s41419-018-1210-9

Cited by 63 publications

(51 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing studies show that lncRNAs could be competing endogenous RNAs (ceRNAs) for miRNAs (Cui et al, ; Li et al, ). Hence, we speculated whether LOC105369748 could be a ceRNA for specific miRNAs.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR‐5095 from MBD2

Changyong

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

A growing number of studies have suggested that long noncoding RNAs (lncRNAs) play critical roles in human malignant cancers, including hepatocellular carcinoma (HCC). However, the functions of most lncRNAs have not been elucidated in HCC. In the present study, we explored the potential functions of a novel lncRNA LOC105369748 in the HCC progression. We identified that LOC105369748 expression was significantly elevated in HCC tissues compared with normal tissues based on bioinformatics analysis, quantitative reverse transcription polymerase chain reaction (qRT‐PCR) analysis and in situ hybridization (ISH) examination. Moreover, we found that the LOC105369748 overexpression was associated with poor prognosis in patients with HCC. Then we measured the effects of LOC105369748 on HCC cell proliferation, migration, invasion, and epithelial‐to‐mesenchymal transition (EMT). And our results demonstrated that LOC105369748 exerted oncogenic roles. In terms of mechanism, LOC105369748 was shown to promote MBD2 expression through competitively binding to microRNA(miR)‐5095 in HCC. In conclusion, our findings elucidate that the LOC105369748/miR‐5095/MBD2 signaling axis regulates the HCC progression and may be a novel therapeutic avenue.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Total protein was isolated from cultured cell lines using the radioimmunoprecipitation (RIPA) buffer (Cell Signaling Technology, Inc., Danvers, MA). Western blot analysis was performed according to the previous study (Li et al, ). The primary antibodies are as follows: anti‐E‐cadherin (1:2,000; cat.…”

Section: Methodsmentioning

confidence: 99%

Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR‐5095 from MBD2

Changyong

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Another identified lncRNA, PPP1R26-AS1, is reported in association with breast cancer in GWAS using the Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases (Xu et al, 2017). Moreover, PPP1R26-AS1 and some other lncRNAs have been shown to be associated with luminal B subtypes of breast cancer (Xu et al, 2017;Li et al, 2018). Interestingly, the proteincoding partner of PPP1R26-AS1 lncRNA, PPP1R26, was also differentially expressed in all sets of neuroblastoma, which could shed light on the molecular function of the identified lncRNA.…”

Section: Discussionmentioning

confidence: 99%

Identification of lncRNAs Associated With Neuroblastoma in Cross-Sectional Databases: Potential Biomarkers

Prajapati

Fatma

Fatima

et al. 2019

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have emerged as an important regulatory control in biological systems. Though the field of lncRNA has been progressing rapidly, a complete understanding of the role of lncRNAs in neuroblastoma pathogenesis is still lacking. To identify the abrogated lncRNAs in primary neuroblastoma and in the metastasized as well as the relapsed form of neuroblastoma, we analyzed an RNA-seq dataset on neuroblastoma that is available online to identify the lncRNAs that could potentially be contributing to the biology of neuroblastoma. The identified lncRNAs were further scrutinized using a publicly available epigenetic dataset of neuroblastoma and a cancer database. After this cross-sectional study, we were able to identify three significant lncRNAs, CASC15, PPP1R26-AS1, and USP3-AS1, which could serve as potential biomarkers in clinical studies of neuroblastoma pathogenesis.

show abstract

“…Our group has previously reported that circulating lncRNAs act as potential novel biomarkers for diagnosis and prognosis of non‐small cell lung cancer . Several recent studies have focused on the involvement of lncRNAs in tumor metastasis because these lncRNAs have shown great promise in the discovery of new biomarkers for predicting prognosis in individual patients . Some lncRNAs, such as HCP5, CAR10, NEAT1 and MALAT1, promote lung cancer metastasis via various mechanisms .…”

Section: Introductionmentioning

confidence: 99%

“…10 Several recent studies have focused on the involvement of lncRNAs in tumor metastasis because these lncRNAs have shown great promise in the discovery of new biomarkers for predicting prognosis in individual patients. [11][12][13] Some lncRNAs, such as HCP5, CAR10, NEAT1 and MALAT1, promote lung cancer metastasis via various mechanisms. 7,14,15 These findings suggest that the tumor metastasis-associated lncRNAs in lung cancer have potential prognostic implications.…”

Section: Introductionmentioning

confidence: 99%

Unique metastasis‐associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma

Zhang

Han

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background Local relapses and metastases are primary causes of death in lung cancer patients. In the present study, we aimed to develop a prognostic signature based on metastasis‐associated lncRNAs in patients with lung adenocarcinoma (LUAD). Methods Firstly, the potential metastasis‐associated lncRNAs were identified by analyzing high‐throughput data from The Cancer Genome Atlas (TCGA), and based on which, an lncRNA signature was constructed for prediction of relapse in LUAD patients using Cox proportional hazards regression analysis. Moreover, the prognostic performance of the lncRNA signature was evaluated using Kaplan‐Meier survival analysis, time‐dependent receiver operating characteristic (ROC) curve and Cox analysis, respectively. In addition, the potential metastasis‐associated function of these six lncRNAs was confirmed by lncRNA over‐expression or depletion and in vitro transwell assays in LUAD cells. Results An lncRNA signature consisting of six most important prognostic factors (LINC01819, ZNF649‐AS1, HNF4A‐AS1, FAM222A‐AS1, LINC02323 and LINC00672) was developed. The signature was an independent predictor for patients' relapse‐free survival (RFS), which could provide higher tumor relapse prediction capability compared with the TNM staging system at three years and five years, respectively (P = 0.0209 and P = 0.0468). Furthermore, the combination of this lncRNA signature and TNM stage had better prognostic value than TNM stage alone at three and five years, respectively (P = 0.0006 and P = 0.0096). Additionally, all the lncRNAs of the signature had a regulatory role in the LUAD cell mobility. Conclusions This novel six‐lncRNA signature had considerable prognostic value for prediction of relapse in LUAD patients. Key points Significant findings of the studyThe unique metastasis‐associated lncRNA signature was related to tumor metastasis and prognosis in LUAD patients. What this study addsThis signature had considerable prognostic value for prediction of relapse in LUAD patients.

show abstract

Long noncoding RNA ATB promotes the epithelial−mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer

Cited by 63 publications

References 42 publications

Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR‐5095 from MBD2

Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR‐5095 from MBD2

Identification of lncRNAs Associated With Neuroblastoma in Cross-Sectional Databases: Potential Biomarkers

Unique metastasis‐associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma

Contact Info

Product

Resources

About